The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells

Enzalutamide is a second-generation anti-androgen which has shown increased survival in patients with metastatic prostate cancer. However, some patients do not respond to this therapy or will develop resistance to treatment over time. Signal Transducer and Activator of Transcription 3 (STAT3) is kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Hellsten, Rebecka, Stiehm, Anna, Palominos, Macarena, Persson, Margareta, Bjartell, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344336/
https://www.ncbi.nlm.nih.gov/pubmed/35917644
http://dx.doi.org/10.1016/j.tranon.2022.101495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344336/
https://www.ncbi.nlm.nih.gov/pubmed/35917644
http://dx.doi.org/10.1016/j.tranon.2022.101495

Ejemplares similares